IP Library Granted Patent US 11,135,202
Granted Patent B2
US 11,135,202 · App. 15/474,267 · Granted Oct 5, 2021

Thiazolide compounds for treating viral infections

Inventors: Jean-Francois Rossignol (St. Petersburg, FL); Maria Gabriella Santoro (Rome, IT)
Assignee: Romark Laboratories L.C.
A61K31/426A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,135,202
App. No.
15/474,267
Granted
Oct 5, 2021
Kind
B2
Abstract

Thiazolide compounds, such as nitazoxanide and/or tizoxanide, may be used against viruses belonging to the Picornaviridae family or the Paramyxoviridae family.

Claims (11)

1. A method of reducing a duration of symptoms of a disease or condition having as a sole cause of the disease or condition, Rhinovirus A, comprising administering to a subject in need thereof 500 mg to 700 mg of a thiazolide compound selected from nitazoxanide, tizoxanide and a combination thereof or a pharmaceutically acceptable salt thereof as a monotherapy, wherein the subject has at least one symptom of the disease or condition, said at least one symptom being selected from a fever, feverishness, headache, myalgia, fatigue, cough, nasal obstruction and sore throat, wherein said administering provides a reduction of a duration of the at least one symptom in the subject compared to an average duration of the at least one symptom in an untreated patient population of the disease or condition, wherein the disease or condition has a symptom duration defined by the average duration of the at least one symptom in the untreated patient population.

2. The method of claim 1 , wherein the at least one symptom comprises at least one moderate or severe respiratory symptom selected from cough, sore throat, and nasal obstruction.

3. The method of claim 1 , wherein the at least one symptom comprises:

a fever, at least one moderate or severe respiratory symptom selected from cough, sore throat, and nasal obstruction, and at least one moderate or severe constitutional symptom selected from headache, myalgia, and fatigue.

4. The method of claim 1 , wherein the average duration of the at least one symptom in the untreated patient population is from 92 hours to 298 hours.

5. The method of claim 2 , wherein the average duration of the at least one symptom in the untreated patient population is from 92 hours to 298 hours.

6. The method of claim 3 , wherein the average duration of the at least one symptom in the untreated patient population is from 92 hours to 298 hours.

7. The method of claim 1 , wherein the subject is a human being.

8. A method of treating a disease or condition having as a sole cause of the disease or condition, Rhinovirus A, comprising administering to a subject in need thereof 500 mg to 700 mg of a thiazolide compound selected from nitazoxanide, tizoxanide and a combination thereof or a pharmaceutically acceptable salt thereof as a monotherapy, wherein the subject has at least one respiratory symptom of the disease or condition, said at least one respiratory symptom being selected from cough, nasal obstruction and sore throat.

9. The method of claim 8 , wherein the subject has symptoms of the disease or condition, said symptoms comprise (a) a fever, (b) at least one moderate or severe respiratory symptom selected from cough, sore throat, and nasal obstruction, and (c) at least one moderate or severe constitutional symptom selected from headache, myalgia, and fatigue.

10. The method of claim 8 , wherein the subject is a human being.

Assignments (4)
SECURITY INTEREST Recorded Nov 16, 2019
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 051030/0613 →
SECURITY INTEREST Recorded Jul 2, 2018
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 046254/0524 →
SECURITY INTEREST Recorded Dec 22, 2017
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 044472/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2017
From: ROSSIGNOL, JEAN-FRANCOIS; SANTORO, MARIA GABRIELLA
To: ROMARK LABORATORIES L.C.
Reel/Frame 042302/0250 →
Continuity (2)
Provisional Application 62316463 · Mar 31, 2016
Related Publication 20170281603A1 · Oct 5, 2017